InventisBio Past Earnings Performance
Past criteria checks 0/6
InventisBio has been growing earnings at an average annual rate of 8.5%, while the Biotechs industry saw earnings growing at 5.4% annually.
Key information
8.5%
Earnings growth rate
47.5%
EPS growth rate
Biotechs Industry Growth | 11.3% |
Revenue growth rate | n/a |
Return on equity | -12.9% |
Net Margin | -128.4% |
Next Earnings Update | 23 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How InventisBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 194 | -249 | 68 | 417 |
31 Dec 23 | 186 | -284 | 70 | 443 |
30 Sep 23 | 127 | -340 | 60 | 433 |
30 Jun 23 | 80 | -426 | 63 | 480 |
31 Mar 23 | 0 | -481 | 59 | 464 |
31 Dec 22 | 0 | -483 | 58 | 461 |
30 Sep 22 | 0 | -476 | 54 | 449 |
30 Jun 22 | 0 | -416 | 49 | 386 |
31 Mar 22 | 0 | -411 | 51 | 358 |
31 Dec 21 | 0 | -358 | 48 | 315 |
31 Dec 20 | 0 | -1,053 | 24 | 1,005 |
31 Dec 19 | 55 | -95 | 12 | 131 |
Quality Earnings: 688382 is currently unprofitable.
Growing Profit Margin: 688382 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688382 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare 688382's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688382 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.6%).
Return on Equity
High ROE: 688382 has a negative Return on Equity (-12.89%), as it is currently unprofitable.